№ files_lp_4_process_3_082774
File format: docx Character count: 75480 File size: 80 KB
The document presents the proceedings and decisions from an appeal hearing held by NICE regarding the use of abiraterone for the treatment of newly diagnosed metastatic hormone-naïve prostate cancer.
Year: 2020
Region / City: United Kingdom
Topic: Prostate Cancer, Oncology, Drug Evaluation
Document Type: Appeal Hearing Transcript
Organization: National Institute for Health and Care Excellence (NICE)
Author: Various panel members, including Heather Blake, Professor Nicholas James, and others
Target Audience: Healthcare professionals, decision-makers, cancer advocacy groups
Effective Period: September 2020
Approval Date: 3 September 2020
Date of Changes: None
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Management of Newly Diagnosed Type 1 Diabetes Mellitus in Children at Canberra Health Services
Year: 2024
Region / City: Canberra, Australia
Topic: Paediatric Diabetes Care
Document Type: Clinical Guideline
Organization: Canberra Health Services, Paediatric Endocrinology & Diabetes Service (PEDS)
Target Audience: Paediatric endocrinologists, medical officers, ward nursing staff, diabetes educators
Age Group: Children and adolescents 0–16 years
Scope: Inpatient management of newly diagnosed Type 1 Diabetes Mellitus
Exclusions: Diabetic Ketoacidosis management, Type 2 Diabetes, Cystic Fibrosis Related Diabetes, pre-existing T1DM, outpatient management
Venclexta® (Venetoclax) Tablet 100 mg, 50 mg, Request for Authority Listing for Treatment of Newly Diagnosed Acute Myeloid Leukaemia Ineligible for Intensive Chemotherapy
Year: 2021
Region / city: Australia
Topic: Pharmaceutical Drug Submission
Document type: Resubmission Request
Organization / institution: PBAC
Author: AbbVie Pty Ltd.
Target audience: Healthcare professionals, PBAC
Validity period: Not specified
Approval date: 2021
Date of amendments: Not specified
Call for Quotations for Field Investigator-cum-Laboratory Technician for Research Project on Type of Anemia in Patients with Newly Diagnosed Diabetes Mellitus
Year: 2022
Region / City: Kangra, Himachal Pradesh
Subject: Health
Document Type: Call for Quotations
Organization / Institution: Dr. Rajendra Prasad Government Medical College
Author: Dr. Rashmi Kaul, Prof & Head of Dept. of Pathology
Target Audience: Contractors, Individuals/Agencies for Research Project
Duration: 12 months
Approval Date: 19/3/2022
Amendment Date: 19/4/2022
Contextual Description: A call for quotations for outsourcing a field investigator-cum-laboratory technician for a research project on anemia in diabetic patients at Dr. Rajendra Prasad Government Medical College.
Invitation to Participate in a National Survey for Patients Diagnosed with Axial Spondyloarthropathy
Year: 2022
Region / City: Wales
Topic: Axial Spondyloarthropathy
Document Type: Survey Invitation
Organization / Institution: National Axial Spondyloarthritis Society (NASS)
Author: National Axial Spondyloarthritis Society (NASS)
Target Audience: Patients recently diagnosed with Axial Spondyloarthropathy (Axial Spondyloarthritis, Ankylosing Spondylitis, or Axial SpA)
Duration: N/A
Approval Date: N/A
Revision Date: N/A
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Year: 2018
Region / city: Northern Ireland
Topic: Cancer survival trends, international comparison
Document type: Research paper
Organization / institution: NICR
Author: Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Michel P Coleman, et al.
Target audience: Health professionals, researchers, policymakers
Effective period: 2000–2014
Approval date: Not specified
Date of changes: Not specified
Journal: Lancet
DOI: doi.org/10.1016/S0140-6736(17)33326-3
Funders: International contributors including Cancer Focus and Public Health Agency via NICR
Conclusion: International differences in cancer survival exist
What this means for the service: Northern Ireland compares well for cancer survival internationally but not when compared to similar countries in Europe.
Topics: hormone-nave ID945 Diagnosed